Current Opinion in Rheumatology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Rheumatology is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Daniel E. Furst
Daniel E. Furst is the first Carl M. Pearson Professor of Medicine at the University of California, Los Angeles (UCLA), Medical Center, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, USA. Dr Furst received his MD from Johns Hopkins University, where he also completed his internship and residency. He completed two fellowships, one in rheumatology at UCLA Medical Center, and a second in clinical pharmacology at the University of California, San Francisco Medical Center, USA.
After serving as Assistant Professor of medicine/rheumatology at the UCLA Medical Center and Associate Professor of internal medicine/rheumatology at the University of Iowa Carver College of Medicine, USA, Dr Furst became Clinical Professor in the Department of Medicine, Division of Rheumatology and Connective Tissue Research at the University of Medicine and Dentistry of New Jersey, USA, and Director of AI/P Clinical Research at Ciba Geigy Pharmaceuticals. He then moved to Seattle, USA, where he was Clinical Professor of medicine at the University of Washington, then Director of clinical research programs and Director of the Arthritis Clinical Research Unit at the Virginia Mason Medical Center. He then took up his present position at UCLA.
Dr Furst has been on a number of national committees concerned with rheumatic therapeutics, including as a member and Fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the FDA. He was Chairman of the Innovative Therapies Meeting of the American College of Rheumatology and Clinical Abstracts Selection Chair for the National American College of Rheumatology meeting. He recently was co-leader of the ACR recommendations for the use of non-biologic and biologic therapies in RA. He has served or is serving on the editorial boards of Inpharma, Clinical Drug Investigation, Drugs, The Journal of Clinical Rheumatology, and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, The New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy and the Annals of the Rheumatic Diseases. Dr Furst has published more than 450 articles and 14 books, including more than 220 research articles and more than 230 reviews or chapters in addition to two editions of a book on scleroderma. Dr Furst's areas of research interest include the clinical pharmacology of anti-rheumatic drugs and biologics, and the pathophysiology and treatment of systemic sclerosis.
Philip Clements, MD, MPH, is an Emeritus Professor of Medicine Rheumatology at UCLA, USA, who has devoted most of his 42-year career to the care of and management of patients with systemic sclerosis and to the scientific evaluation of managements and therapies for these patients. Specifically he has participated in the development, conduct and analysis of many clinical studies and trials in systemic sclerosis: 1) the clinical description of the various organ involvements in patients with systemic sclerosis (pulmonary hypertension, gastrointestinal involvements, interstitial lung disease, muscle and joint involvement) as witnessed in prospective longitudinal trials or cohorts; 2) the development and validation of clinical outcome measures (i.e., modified Rodnan skin thickness score, forced vital capacity, disability index of the Health Assessment Questionnaire, UCLA-SCTC Gastrointestinal Tract Questionnaire) to measure change over time; and 3) the evaluation of therapeutic strategies (i.e., D-penicllamine, chlorambucil, N-acetylcysteine, cyclosporine, rapamycin, imatinib, cyclophosphamide, mycophenolate) designed to improve the function and quality of life in patients with systemic sclerosis. He continues to move forward in all these areas for the near future.
Dr Hector Chinoy is a Senior Clinical Lecturer in Rheumatology at The University of Manchester, UK, where he conducts an active programme of research and is Program Director for the Clinical Rheumatology MSc Programme, and is also an Honorary Consultant Rheumatologist at Salford Royal NHS Foundation Trust, UK. At the University of Nottingham, UK, Dr Chinoy completed his medical degree in 1996, carried out medical training in Nottingham, Sheffield and Manchester, and trained in rheumatology from 2001 to 2009. He completed an arthritis research UK fellowship at The University of Manchester and was awarded a PhD in 2007. He has research interests in inflammatory myopathy, immunogenicity of biologic therapy, immunogenetic risk factors and how these correlate with novel serological biomarkers and clinical outcomes, and supervises a number of PhD students. At Salford Royal, he runs general rheumatology, adult neuromuscular and combined psoriasis-psoriatic arthritis clinics. He is a reviewer for several major rheumatology peer-reviewed journals and is on the abstract selection committee for the British Society for Rheumatology, European League Against Rheumatism and American College of Rheumatology annual conferences. He is co-chair of UKMYONET, a national consortium which fosters collaborative research in inflammatory myopathy, co-chair of the Euromyositis registry, a consortium that collects standardised clinical data over 20 countries, and is a member of the Arthritis Research UK Autoimmune Rheumatic Disease Clinical Trials Subcommittee.
Robert G. Cooper
Robert G. Cooper is a Professor of Medicine in the MRC/ARUK Institute of Ageing and Chronic Disease in the University of Liverpool, UK, and an Honorary Professor of Rheumatology in the Centre for Integrated Genomic Medical Research (CIGMR) in the University of Manchester, UK. His recent research has focused on the elucidation of disease mechanisms in the idiopathic inflammatory myopathies, and to facilitate such research he set up the UK Adult onset Myositis Immunogenetic Collaboration (AOMIC) in 1999, becoming the UK MYONET in 2008. This collaboration has recruited more than 1200 adult UK cases to date, and is supported by grants from the ARUK and from the Association Francaise contra les Myopathies. He was also a cofounder of the EU MYONET, with main aim to foster collaborative myositis research in Europe and which is supported by a European Science Foundation funded networking grant. He is also a member of MYOGEN, a fully international myositis collaboration which has recently delivered the first genome wide association scan in dermatomyositis. Only genes within the HLA region reached whole genome level significance, though some of the “pan autoimmunity” genes were associated with increased susceptibility risk at lower significance. During this time Prof. Cooper has worked closely with internationally renowned serology laboratories in Pittsburgh, US, and in Bath, UK, and many exiting new myositis specific antibodies have been discovered and their clinical associations characterised. His recent academic appointment in Liverpool is to enable him to study mechanisms causing the non-immune muscle dysfunction which is known to occur in myositis. Prof. Cooper has written over 100 peer reviewed scientific papers and reviews, and a number of book chapters on myositis, including in the Oxford Textbook of Rheumatology, and the EULAR Textbook of Rheumatology. He remains clinically active, undertaking generic rheumatology as well as tertiary adult myositis clinics in Liverpool and Manchester. He has just finished his term of office on the scientific advisory board of The Myositis Association.